WO2013127782A3 - Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart - Google Patents

Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart Download PDF

Info

Publication number
WO2013127782A3
WO2013127782A3 PCT/EP2013/053800 EP2013053800W WO2013127782A3 WO 2013127782 A3 WO2013127782 A3 WO 2013127782A3 EP 2013053800 W EP2013053800 W EP 2013053800W WO 2013127782 A3 WO2013127782 A3 WO 2013127782A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
heart
storage diseases
individual forms
markers
Prior art date
Application number
PCT/EP2013/053800
Other languages
German (de)
French (fr)
Other versions
WO2013127782A2 (en
Inventor
Uwe Kühl
Heinz-Peter Schultheiss
Dirk Lassner
Maria ROHDE
Original Assignee
Charité - Universitätsmedizin Berlin
Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charité - Universitätsmedizin Berlin, Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh filed Critical Charité - Universitätsmedizin Berlin
Priority to DE112013001154.9T priority Critical patent/DE112013001154A5/en
Priority to EP13712154.7A priority patent/EP2820131A2/en
Publication of WO2013127782A2 publication Critical patent/WO2013127782A2/en
Publication of WO2013127782A3 publication Critical patent/WO2013127782A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The invention relates to the use of certain microRNAs and/or genes, both individually and as a combination of several, in the form of profiles as markers for identifying individual forms of non-ischemic cardiomyopathies or storage diseases of the heart, and to their use in diagnostic systems for identifying individual forms of non-ischemic cardiomyopathies or storage diseases of the heart, which includes at least some of these microRNAs and/or genes. The invention furthermore relates to a method for identifying and differentiating between individual forms of non-ischemic cardiomyopathies or storage diseases of the heart using at least individual ones of these microRNAs and/or genes. The invention further relates to a medicament which contains at least one nucleic acid which includes a sequence which is identical or complementary to the sequence of one of these microRNAs.
PCT/EP2013/053800 2012-02-27 2013-02-26 Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart WO2013127782A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE112013001154.9T DE112013001154A5 (en) 2012-02-27 2013-02-26 Use of microRNAs or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or memory diseases of the heart
EP13712154.7A EP2820131A2 (en) 2012-02-27 2013-02-26 Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101557.0 2012-02-27
DE102012101557A DE102012101557A1 (en) 2012-02-27 2012-02-27 Use of microRNAs or genes as markers for the identification, diagnosis and therapy of individual non-ischemic cardiomyopathies or memory diseases of the heart

Publications (2)

Publication Number Publication Date
WO2013127782A2 WO2013127782A2 (en) 2013-09-06
WO2013127782A3 true WO2013127782A3 (en) 2013-11-21

Family

ID=47997358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/053800 WO2013127782A2 (en) 2012-02-27 2013-02-26 Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart

Country Status (3)

Country Link
EP (1) EP2820131A2 (en)
DE (2) DE102012101557A1 (en)
WO (1) WO2013127782A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450698A (en) * 2014-12-11 2015-03-25 中国计量学院 Spider mitochondria ND4 gene complete sequence amplification primer and identification method thereof
WO2016133395A1 (en) 2015-02-20 2016-08-25 Rijksuniversiteit Groningen Circulating micrornas in patients with acute heart failure
SG10201910479UA (en) * 2015-05-08 2020-03-30 Agency Science Tech & Res Method for diagnosis and prognosis of chronic heart failure
DE102015216521B3 (en) * 2015-08-28 2017-01-26 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Use of specific genes for the diagnostic differentiation of eosinophilic myocarditis from other fulminant inflammatory myocardial diseases
DE102015216782B3 (en) * 2015-09-02 2017-01-26 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Use of microRNAs circulating in the blood serum or blood plasma for identifying patients who are subject to biopsy and as markers for the differential diagnosis of individual non-ischemic cardiomyopathies or cardiac memory disorders
WO2017076974A1 (en) * 2015-11-05 2017-05-11 Academisch Medisch Centrum Biomarker for risk stratification in cardiovascular disease
EP3375458A1 (en) * 2017-03-14 2018-09-19 I.C.G.E.B. International Centre for Genetic Engineering and Biotechnology Microrna hsa-mir-665 in cardiac hypertrophy
US11225660B2 (en) 2017-10-12 2022-01-18 Emory University Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
CN108611421B (en) * 2018-05-15 2021-07-27 唐山市人民医院 MicroRNA-10b-3p for detecting esophageal squamous carcinoma marker and application thereof in kit
JP2021529202A (en) * 2018-06-28 2021-10-28 ユナイテッド キングダム リサーチ アンド イノベーション MicroRNA targeting agents for the treatment of heart disease
CN113454241A (en) * 2018-12-10 2021-09-28 赛拉预测公司 Nucleic acid biomarkers of placental dysfunction
EP3674420A1 (en) * 2018-12-28 2020-07-01 Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana Method for predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy
CN111154870B (en) * 2019-08-05 2023-06-23 江苏省肿瘤医院 Biomarker for nasopharyngeal carcinoma metastasis diagnosis and/or prognosis evaluation
CN112961912A (en) * 2020-12-31 2021-06-15 郑州大学第一附属医院 Exosome miRNA (micro ribonucleic acid) serving as molecular marker for diagnosing coronary heart disease and application of exosome miRNA
CN112813158B (en) * 2021-03-11 2022-12-13 石家庄市人民医院 MiRNA marker related to myocardial fibrosis disease auxiliary diagnosis and application thereof
CN113846098A (en) * 2021-09-18 2021-12-28 中国医学科学院基础医学研究所 Small RNA and application thereof in treatment of cardiovascular diseases
CN114081895B (en) * 2021-11-18 2023-08-04 佳木斯大学 miRNA for treating diabetic retinopathy and application thereof
CN115418397B (en) * 2022-04-19 2023-09-19 刘琳 Biomarker for auxiliary diagnosis of dilated cardiomyopathy and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (en) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
WO2009151600A2 (en) * 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
WO2010141546A1 (en) * 2009-06-02 2010-12-09 University Of Miami Diagnostic transcriptomic biomakers in inflammatory cardiomyopathies
WO2011072177A2 (en) * 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008275877B2 (en) * 2007-07-18 2015-01-22 The Regents Of The University Of Colorado, A Body Corporate Differential expression of microRNAs in nonfailing versus failing human hearts
WO2009033185A1 (en) * 2007-09-06 2009-03-12 University Of Massachusetts Virus-specific mirna signatures for diagnosis and therapeutic treatment of viral infection
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (en) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
WO2009151600A2 (en) * 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
WO2010141546A1 (en) * 2009-06-02 2010-12-09 University Of Miami Diagnostic transcriptomic biomakers in inflammatory cardiomyopathies
WO2011072177A2 (en) * 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
B. HEIDECKER ET AL: "Transcriptomic Biomarkers for the Accurate Diagnosis of Myocarditis", CIRCULATION, vol. 123, no. 11, 7 March 2011 (2011-03-07), pages 1174 - 1184, XP055062635, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.110.002857 *
BENAKANAKERE MANJUNATHA R ET AL: "Modulation of TLR2 Protein Expression by miR-105 in Human Oral Keratinocytes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 284, no. 34, 21 August 2009 (2009-08-21), pages 23107 - 23115, XP002544552, ISSN: 0021-9258, [retrieved on 20090609], DOI: 10.1074/JBC.M109.013862 *
FICHTLSCHERER STEPHAN ET AL: "Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, HIGHWIRE PRESS, PHILADELPHIA, PA, US, vol. 31, no. 11, November 2011 (2011-11-01), pages 2383 - 2390, XP008147068, ISSN: 1524-4636, DOI: 10.1161/ATVBAHA.111.226696 *
GERMAN HEART FAILURE NETWORK ET AL: "Gene expression profiling from endomyocardial biopsy tissue allows distinction between subentities of dilated cardiomyopathy", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 136, no. 2, 12 May 2008 (2008-05-12), pages 360 - 369.e1, XP023610234, ISSN: 0022-5223, [retrieved on 20080512], DOI: 10.1016/J.JTCVS.2008.03.016 *
HIDEHITO FUNAHASHI ET AL: "Altered microRNA expression associated with reduced catecholamine sensitivity in patients with chronic heart failure", JOURNAL OF CARDIOLOGY, vol. 57, no. 3, 2 March 2011 (2011-03-02), pages 338 - 344, XP055062634, ISSN: 0914-5087, DOI: 10.1016/j.jjcc.2011.01.009 *
KASEY C. VICKERS ET AL: "MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins", NATURE CELL BIOLOGY, vol. 13, no. 4, 20 March 2011 (2011-03-20), pages 423 - 433, XP055062682, ISSN: 1465-7392, DOI: 10.1038/ncb2210 *
M. F. CORSTEN ET AL: "Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease", CIRCULATION: CARDIOVASCULAR GENETICS, vol. 3, no. 6, 4 October 2010 (2010-10-04), pages 499 - 506, XP055062726, ISSN: 1942-325X, DOI: 10.1161/CIRCGENETICS.110.957415 *
S. V. NAGA PRASAD ET AL: "Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling Networks", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 40, 29 July 2009 (2009-07-29), pages 27487 - 27499, XP055062050, ISSN: 0021-9258, DOI: 10.1074/jbc.M109.036541 *
See also references of EP2820131A2 *

Also Published As

Publication number Publication date
WO2013127782A2 (en) 2013-09-06
DE112013001154A5 (en) 2014-12-11
DE102012101557A1 (en) 2013-08-29
EP2820131A2 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
WO2013127782A3 (en) Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart
IL285107A (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
IL250539A0 (en) Modified nucleotides for synthesis of nucleic acids, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes
WO2012174256A3 (en) Dna methylation profiles in cancer
IL229070A0 (en) Methods of identification and diagnosis of lung diseases using classifiction systems and kits thereof
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
EP4273160A3 (en) Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
GB2500120B (en) Method of producing fluid identification system including DNA
IL222252A (en) System, assembly and method for the detection and diagnosis of biological rhythm disorders
WO2013170170A3 (en) Compositions and methods for gene therapy
UA117098C2 (en) Microrna compounds and methods for modulating mir-21 activity
EP2849632A4 (en) Clinical diagnostic system including instrument and cartridge
EP2901345A4 (en) System for genome analysis and genetic disease diagnosis
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
ITMI20110357A1 (en) MICROFLUID SYSTEM FOR PURPOSES OF ANALYSIS AND DIAGNOSIS, AS WELL AS THE CORRESPONDING PROCEDURE FOR PRODUCING A MICROFLUID SYSTEM
WO2012158780A3 (en) Lung cancer signature
HK1175208A1 (en) Indexes for multiplex nucleic acid sequencing and use thereof
BR112014027905A2 (en) antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent.
WO2013124807A3 (en) Oligonucleotides for modulating gene expression and uses thereof
WO2012056451A3 (en) Peripheral blood gene markers for early diagnosis of parkinson's disease
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
EP2839031A4 (en) Detection of target nucleic acid sequence by pto cleavage and extension-dependent signaling oligonucleotide cleavage
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy
EP2845910A4 (en) Probe or probe set for evaluating influence of ultraviolet ray on skin, and nucleic acid microarray
WO2013144663A3 (en) Method of determination of neutral dna sequences in the genome, system for targeting sequences obtained thereby and methods for use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13712154

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 112013001154

Country of ref document: DE

Ref document number: 1120130011549

Country of ref document: DE

REEP Request for entry into the european phase

Ref document number: 2013712154

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013712154

Country of ref document: EP